BD is a global medical technology leader with a mission to 'Advance the world of health™.' The company has achieved sustained growth through a portfolio of essential, high-volume consumables and strategic expansion into higher-growth areas like biosciences, informatics, and connected care. Its current strategy focuses on portfolio simplification, innovation in smart, connected devices, and leveraging data through platforms like BD Incada™ to improve clinical and operational outcomes across the healthcare continuum.
Infection PreventionMedication ManagementDiagnosticsSurgical InterventionUrologyDiabetes CareBiomedical Research
Technology Platform
BD's core technology is an integrated ecosystem of connected medical devices, automation systems, and data analytics, centered on the vendor-agnostic BD Incada™ Connected Care Platform, which activates data to improve clinical and operational outcomes.
Funding History
2
Total raised:$10B
Debt$4BUndisclosed
Debt$6BUndisclosed
Opportunities
Significant opportunities exist in the digitization of healthcare through the BD Incada™ platform, the growing demand for automation and safety in medication management and diagnostics, and the expansion of healthcare access in emerging markets.
The shift to outpatient care also presents a tailwind for BD's tailored solutions.
Risk Factors
Key risks include sustained pricing pressure from healthcare cost containment, potential supply chain and manufacturing disruptions, regulatory hurdles and product liability litigation, and execution risks associated with the company's strategic portfolio transformation and digital integration.
Competitive Landscape
BD faces intense competition from large, diversified medtech peers (e.g., Medtronic, J&J, Abbott) and focused specialists across its segments. Its competitive edge lies in its global scale, embedded installed base, trusted brand, and evolving ecosystem of connected devices and data solutions.
